BioMarin Withdraws Roctavian

This announcement appears in BioMarin’s 2025 full-year financial report: “Following the company’s October announcement to explore options to divest ROCTAVIAN, BioMarin undertook a comprehensive effort to identify a potential buyer. Despite these efforts, BioMarin was unable to identify a qualified buyer and has decided to withdraw ROCTAVIAN from the market voluntarily.” There are no FVIII […]

Comments (0)

Bleeding Disorders

Mar 2 2026

george

Emicizumab Dosage

Here is an open-access article on current emicizumab dosage: van der Zwet K, de Vos ADW, Cnossen MH, et al; OPTI-CLOT Study Group and SYMPHONY Consortium. Pharmacokinetic-guided dose reduction of emicizumab in congenital hemophilia A: interim analysis of the DosEmi study. J Thromb Haemost. 2026;24:890–99. doi: 10.1016/j.jtha.2025.10.029. PMID: 41207564. Abstract Background Emicizumab provides effective prophylaxis […]

Bleeding Disorders

Case Series: Emicizumab Therapy in Acquired Hemophilia A

Here is an open-access article describing emicizumab Rx in acquired hemophilia A: Calcaterra I, De Luca C, D’Errico G, et al. Emicizumab in acquired hemophilia A: a real-world case series with patient-level outcome analysis. Semin Thromb Hemost. 2026 doi: 10.1055/a-2788-1642. Epub ahead of print. PMID: 41534873. Abstract Acquired Hemophilia A (AHA) is a rare bleeding […]

Bleeding Disorders

Field Study Compares OSA With CSA for Measuring Efanesoctocog Alfa

Here is an open-access article contrasting the validity of OSA versus CSA for measuring efanesoctocog alfa (Altuviiio®) spiked into normal plasma: Pipe S, Sadeghi-Khomami A, Konkle BA, et al. A global comparative field study to evaluate the factor VIII activity of efanesoctocog alfa by one-stage clotting and chromogenic substrate assays at clinical haemostasis laboratories. Haemophilia. […]

Factor Assays

What is Red Light Therapy?

Check with your medical library for this in-depth review of red light Rx efficacy: Fan BE, Pasalic L, Hew YY, Lippi G, Favaloro EJ. Red light therapy in thrombosis and hemostasis. Semin Thromb Hemost. 2026;52:266–72. doi: 10.1055/a-2717-5157. PMID: 41062078. Abstract Red light therapy is emerging as a potential non-pharmacological modulator of thrombosis and hemostasis. Photobiomodulation […]

Antiplatelet Therapy

Enhanced Coagulation Potential FVIII

See this open-access article that describes a synthetic enhanced coagulation potential FVIII. This preparation reflects the enhanced activity FIX Padua. Kashiwakura Y, Nakajima Y, Horinaka K, et al. Engineered coagulation factor VIII with enhanced secretion and coagulation potential for hemophilia A gene therapy. Blood. 2026;147:402–15. doi: 10.1182/blood.2025028481. PMID: 41198051. Abstract Click here for the visual […]

Bleeding Disorders

Review: VWD Type 2A

From Emmanuel Favaloro, PhD, Editor-in-Chief, Seminars in Thrombosis and Hemostasis: 2026 marks the 100th anniversary of the initial publication of a bleeding disorder, “pseudo-hemophilia’ that was later to become known as von Willebrand disease. Seminars in Thrombosis and Hemostasis will publish several papers on VWD in 2026. This is the first one in the queue–on […]

Bleeding Disorders

Low-dose Emicizumab Efficacy

Obtain this clinical research article on low-dose emicizumab therapy from your medical library: Datta G, Verma SP, Sinha S, et al. Bridging the Gap: Efficacy of low-dose emicizumab in haemophilia A with or without inhibitors. Haemophilia. 2026. doi: 10.1111/hae.70211. PMID: 41549560. ABSTRACT Introduction Emicizumab has proven to be a turning point in the management of […]

Bleeding Disorders

VWD In Women: Non-bleeding Health Issues

Click to read this open-access article that addresses the reproductive, medical, skeletal, psychosocial, and economic impact of VWD in women. Swan D, Sholzberg M, Bannow BS, Thachil J. Von Willebrand disease: more than just a bleeding disorder. Res Pract Thromb Haemost. 2025;10:103276. doi: 10.1016/j.rpth.2025.103276. PMID: 41536292; PMCID: PMC12796595. Abstract Von Willebrand disease (VWD) is the […]

Bleeding Disorders

Retrospective Comparison of rVWF versus pdVWF During Hospitalization

Here is an open-access article describing the efficacy of vonicog alfa versus plasma-derived VWF: Horvais V, Ternisien C, Denis-Le-Sève J, et al. Vonicog alfa versus plasma-derived von Willebrand factor during hospitalization: results of an observational retrospective multicenter study. Semin Thromb Hemost. 2026. doi: 10.1055/a-2779-9176. PMID: 41529718. Abstract Available products for the treatment of von Willebrand […]

Comments (0)

Bleeding Disorders

Bleeding Disorders

BioMarin Withdraws Roctavian

Emicizumab Dosage

Case Series: Emicizumab Therapy in Acquired Hemophilia A

Field Study Compares OSA With CSA for Measuring Efanesoctocog Alfa

What is Red Light Therapy?

Enhanced Coagulation Potential FVIII

Review: VWD Type 2A

Low-dose Emicizumab Efficacy

VWD In Women: Non-bleeding Health Issues

Retrospective Comparison of rVWF versus pdVWF During Hospitalization

George Fritsma MS MLS

Cheat Sheets from George

Questions or Comments?

Quick Question